Neuroprotective and/or disease-modifying treatments are urgently needed for Parkinson's disease. This Review describes how an increased understanding of genetic mutations that lead to Parkinson's disease, better translation between preclinical animal models and clinical research, and improved design of future clinical trials are priorities for overcoming the limitations of current therapies.
- Wassilios G. Meissner
- Mark Frasier
- Erwan Bezard